Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Core Insights - The study demonstrates the potential of hypoimmune-modified islet cells to treat type 1 diabetes without the need for immunosuppression, showing sustained insulin production over a 14-month period [1][2][3] - Sana Biotechnology is advancing its SC451 therapy, which aims to provide a one-time treatment for type 1 diabetes, with plans to file an Investigational New Drug (IND) application and initiate a Phase 1 trial as early as this year [1][3][7] Study Results - 14-month follow-up data indicates that C-peptide levels, a biomarker for insulin production, remained stable and comparable to the initial six months of the study, with improvements noted in glycemic control [2][6] - The study found no safety issues, and the transplanted cells demonstrated long-term survival and function, evading immune detection [3][4][6] Technology and Methodology - Sana's hypoimmune platform (HIP) allows for the transplantation of allogeneic cells without immunosuppression, addressing both allogeneic and autoimmune rejection in type 1 diabetes [4][7] - The study involved the transplantation of UP421, derived from deceased donor islet cells, into patients, with a focus on safety and cell function [5][6] Future Directions - The company aims to enhance the scalability of its therapies, with SC451 being a key focus for providing durable blood glucose control without the need for exogenous insulin [3][7] - Collaboration with Uppsala University Hospital continues to be pivotal in advancing the research and development of hypoimmune-modified therapies [3][8]